Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Protagonist Therapeutics Inc
(NQ:
PTGX
)
35.55
-0.16 (-0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
71 Biggest Movers From Yesterday
April 27, 2022
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet
April 26, 2022
U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Why Protagonist Therapeutics Shares Are Crashing Today
April 26, 2022
Via
Benzinga
Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech
March 16, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 26, 2022
Via
Benzinga
Stocks Flounder As Wall Street Rotates Out Of Tech
April 26, 2022
Big Tech stocks are struggling ahead of several key earnings reports.
Via
Talk Markets
Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump
April 26, 2022
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 400 points on Tuesday.
Via
Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
April 26, 2022
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...
Via
Benzinga
The Daily Biotech Pulse - Tuesday, April,26
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Talk Markets
Futures Slide Ahead Of Tech Earnings Deluge
April 26, 2022
Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices.
Via
Talk Markets
Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points
April 26, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Tuesday.
Via
Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 26, 2022
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
April 26, 2022
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...
Via
Benzinga
Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint
April 25, 2022
Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
Via
Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
April 21, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm
April 20, 2022
From
The Schall Law Firm
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 20, 2022
Gainers
Via
Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX
April 20, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 14, 2022
Gainers
Via
Benzinga
51 Biggest Movers From Thursday
April 18, 2022
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...
Via
Benzinga
Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern
April 14, 2022
The FDA could revoke a key designation for one of Protagonist's leading drugs.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
April 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 14, 2022
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!
Via
InvestorPlace
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
April 14, 2022
Protagonist Therapeutics Inc (NASDAQ: PTGX)
Via
Benzinga
Protagonist Therapeutics's Return On Capital Employed Overview
March 03, 2022
Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last...
Via
Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
December 03, 2021
Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.